Spero Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 27, 2025. The company also provided an update on its pipeline, including a significant strategic decision.
Following a pipeline review and reprioritization, Spero Therapeutics decided to discontinue its SPR206 program. This move further concentrates the company's resources on its remaining lead asset.
The company confirmed it is preparing for the pre-specified interim analysis of the Phase 3 PIVOT-PO trial for tebipenem HBr in the next quarter. Development of the oral SPR720 program remains suspended as the company completes a comprehensive data review.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.